Literature DB >> 10334699

The Valenti procedure for hallux limitus: a long-term follow-up and analysis.

D H Kurtz1, J C Harrill, B I Kaczander, M G Solomon.   

Abstract

A retrospective analysis of the long-term efficacy of the Valenti procedure for hallux limitus was performed from 1989 to 1997. A total of 33 patients (36 procedures) were selected, surveyed, and examined. Preoperative and postoperative radiographic evaluations and levels of function and pain were obtained from medical records. Complications and patient satisfaction data were collected and reviewed. The patients were evaluated clinically and radiographically. The average age of the patient at the time of surgery was 50.6 years (range, 35-75 years) with an average follow-up of 4.16 years (range, 1-9 years). The average grade of hallux limitus/rigidus was grade II. Five patients were classified as grade I, 23 as grade II, five as grade III, and none as grade IV, based on the modified Drago/Regnauld grading system. Subjective results were calculated based on the American Orthopedic Foot and Ankle Society clinical rating system. Twenty-two patients were rated as having an excellent result, 11 had good results, two had fair results, and one patient had a poor result. We conclude that the Valenti arthroplasty for symptomatic hallux rigidus/limitus is a good procedure for arthritic and degenerated first metatarsophalangeal joints where implant arthroplasty, osteotomy, or arthrodesis are not viable options. Advantages include increased range of motion, decreased postoperative pain, technical ease of performance, maintenance of intrinsic musculature, and rapid return to closed footgear.

Entities:  

Mesh:

Year:  1999        PMID: 10334699     DOI: 10.1016/s1067-2516(99)80023-4

Source DB:  PubMed          Journal:  J Foot Ankle Surg        ISSN: 1067-2516            Impact factor:   1.286


  1 in total

1.  [The Valenti resection arthroplasty in the treatment of advanced hallux rigidus].

Authors:  Kai Olms; John F Grady; Arndt P Schulz
Journal:  Oper Orthop Traumatol       Date:  2008-12       Impact factor: 1.154

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.